Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety

InnoCare Pharma has unveiled promising preclinical data for its novel B7-H3 targeted antibody-drug conjugate (ADC), ICP-B794, at the 2026 AACR Annual Meeting. This ADC employs a unique linker-payload system, demonstrating potent anti-tumor activity across various preclinical tumor models while maintaining a significantly larger safety window compared to existing therapies. Currently, ICP-B794 is undergoing a Phase I dose-escalation clinical trial, positioning it as a potential game-changer in the ADC landscape.

The significance of ICP-B794 lies in its innovative design, which incorporates an irreversible connector and a highly hydrophilic linker, leading to enhanced stability and efficacy. In vitro assays revealed that ICP-B794 exhibits superior cell-killing activity compared to other B7-H3 ADCs, and in vivo studies suggest it can achieve therapeutic outcomes even at lower doses. Notably, ICP-B794 shows potential to overcome drug resistance commonly associated with other B7-H3-targeting therapies. Safety evaluations have also yielded encouraging results, with a safety window exceeding 200-fold, highlighting its promise for clinical application.

The implications of this research extend beyond immediate therapeutic applications. The enhanced drug-to-antibody ratio (DAR) stability and low payload release in human plasma may shift current paradigms in ADC development, particularly in addressing drug resistance mechanisms. As InnoCare advances ICP-B794 through clinical trials, it could accelerate the timeline for ADCs targeting B7-H3, potentially leading to more effective treatments for cancers that are currently difficult to manage. This development underscores the importance of innovative linker-payload technologies in enhancing ADC efficacy and safety profiles.

Source: globenewswire.com